TGFB1 and pulmonary fibrosis: This was recently shown in a chronic graft-versus-host disease model where inhibition of the 5-HT2B receptor using a highly selective antagonist resulted in reduced dermal fibrosis and lung fibrosis as well as a decreased Smad 2/3 phosphorylation, suggesting TGF-β involvement [50] (Figure 1).